Analysts from UOB Kay Hian and DBS Group Research have maintained their "buy" calls on Hong Leong Asia (HLA) following its half year ending June results announcement on August 12.

CGS-CIMB Research has also maintained its "add" call for HLA.

UOB Kay Hian analyst John Cheong has kept his target price for HLA unchanged at $1.38 after the company’s 1HFY2021 earnings of $41 million came in line with his expectations.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook